Evidence map›Paper›PMID 24276018›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2014

Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.

Mercedes Martín-Rufián, Renata Nascimento-Gomes, Ana Higuero, Amanda R Crisma, José A Campos-Sandoval, María C Gómez-García, Carolina Cardona, Tzuling Cheng, Carolina Lobo, Juan A Segura and 8 more

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 90 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Mercedes Martín-RufiánDepartment of Molecular Biology and Biochemistry, Faculty of Sciences, Campus de Teatinos, University of Málaga, 29071, Málaga, Spain.
Renata Nascimento-Gomes
Ana Higuero
Amanda R Crisma
José A Campos-Sandoval
María C Gómez-García
Carolina Cardona
Tzuling Cheng
Carolina Lobo
Juan A Segura
Francisco J Alonso
Monika Szeliga
Jan Albrecht
Rui Curi
Javier Márquez
Alison Colquhoun
Ralph J Deberardinis
José M Matés
Universidad de Málaga · ESUniversidade de São Paulo · BRThe University of Texas Southwestern Medical Center · USMossakowski Medical Research Institute, Polish Academy of Sciences · PLPolish Academy of Sciences · PL

Funding

METABOLIC REGULATORS OF TUMOR CELL GROWTHR01CA157996 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI DEBERARDINIS, RALPH J · 2011 to 2017
$2.2M
NCI NIH HHS R01 CA157996
6 · The paper itself

Abstract

unlabelledMitochondrial glutaminase (GA) plays an essential role in cancer cell metabolism, contributing to biosynthesis, bioenergetics, and redox balance. Humans contain several GA isozymes encoded by the GLS and GLS2 genes, but the specific roles of each in cancer metabolism are still unclear. In this study, glioma SFxL and LN229 cells with silenced isoenzyme glutaminase KGA (encoded by GLS) showed lower survival ratios and a reduced GSH-dependent antioxidant capacity. These GLS-silenced cells also demonstrated induction of apoptosis indicated by enhanced annexin V binding capacity and caspase 3 activity. GLS silencing was associated with decreased mitochondrial membrane potential (ΔΨm) (JC-1 dye test), indicating that apoptosis was mediated by mitochondrial dysfunction. Similar observations were made in T98 glioma cells overexpressing glutaminase isoenzyme GAB, encoded by GLS2, though some characteristics (GSH/GSSG ratio) were different in the differently treated cell lines. Thus, control of GA isoenzyme expression may prove to be a key tool to alter both metabolic and oxidative stress in cancer therapy. Interestingly, reactive oxygen species (ROS) generation by treatment with oxidizing agents: arsenic trioxide or hydrogen peroxide, synergizes with either KGA silencing or GAB overexpression to suppress malignant properties of glioma cells, including the reduction of cellular motility. Of note, negative modulation of GLS isoforms or GAB overexpression evoked lower c-myc and bcl-2 expression, as well as higher pro-apoptotic bid expression. Combination of modulation of GA expression and treatment with oxidizing agents may become a therapeutic strategy for intractable cancers and provides a multi-angle evaluation system for anti-glioma pre-clinical investigations. KEY MESSAGE: Silencing GLS or overexpressing GLS2 induces growth inhibition in glioma cell lines. Inhibition is synergistically enhanced after arsenic trioxide (ATO) or H2O2 treatment. Glutatione levels decrease in GLS-silenced cells but augment if GLS2 is overexpressed. ROS synergistically inhibit cell migration by GLS silencing or GLS2 overexpression. c-myc, bid, and bcl-2 mediate apoptosis resulting from GLS silencing or GLS2 overexpression.

Indexed as

Gene SilencingOxidative StressAntioxidantsApoptosisArsenicalsArsenic TrioxideBH3 Interacting Domain Death Agonist ProteinBrain NeoplasmsCell MovementCell ProliferationCell SurvivalFlow CytometryGliomaGlutaminaseGlutathioneHumansAntioxidantsArsenicalsArsenic TrioxideBH3 Interacting Domain Death Agonist ProteinGLS2 protein, humanGLS protein, humanGlutaminaseGlutathioneOxidesProto-Oncogene Proteins c-mycReactive Oxygen Species

Identifiers

PMID24276018
PMCPMC4327995
OpenAlexW2044418897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.